The pharmacology of physostigmine

CNS Drug Reviews

Volumn 4, Issue 2, 1998, Pages 87-136

  Triggle, David J ^b   Mitchell, John M ^c   Filler, Ron ^a,d  

^a Forest Laboratories   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Forest Laboratories Inc ^*  (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Acetylcholinesterase (AChE); Alzheimer's disease; Butyrylcholinesterase (BuChE); Cholinesterase; Neurodegeneration; Physostigmine; Tacrine

Indexed keywords

4 AMINOPYRIDINE; ACETYLCHOLINE; AMYLOID BETA PROTEIN; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CYCLIC AMP PHOSPHODIESTERASE; DYFLOS; ESEROLINE; NEOSTIGMINE; NERVE GROWTH FACTOR RECEPTOR; NICOTINIC RECEPTOR; OXOTREMORINE; PHYSOSTIGMINE; PHYSOSTIGMINE SALICYLATE; PIRENZEPINE; PYRIDOSTIGMINE; RUBRESERINE; SCOPOLAMINE; SODIUM CHLORIDE; TACRINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; BRAIN INJURY; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DOG; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; EYE TOXICITY; HEADACHE; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MEMORY; MYASTHENIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOLOGY; RAT; REVIEW;

EID: 0032461207     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1998.tb00059.x     Document Type: Review

References (291)

1. Aigner TG, Mitchell SJ, Aggleton J, et al. Effects of scopolamine and physostigmine on recognition memory in monkeys with ibotenic-acid lesions of the nucleus basalis of Meynert. Psychopharmacology 1987;92:292-300.
2. Aigner TG, Mitchell SJ, Aggleton JP, et al. Transient impairment of recognition memory following ibotenic-acid lesions of the basal forebrain in macaques. Exp Brain Res 1991;86:18-26.
3. Alberch J, Carman-Krzan M, Fabrazzo M, Wise BC. Chronic treatment with scopolamine and physostigmine changes nerve growth factor (NGF) receptor density and NGF content in rat brain. Brain Res 1991;542:233-240.
4. Alexandre JM, Menard J, Chevillard C, Schmitt H. Increased plasma renin activity induced in rats by physostigmine and effects of alpha-and beta-receptor blocking drugs thereon. Eur J Pharmacol 1970;12:127-131.
5. Allderdice PW, Gardner HAR, Galutira D, Lockridge O, La Du BN, McAlpine PJ. The cloned butyrylcholinesterase (BChE) gene maps to a single chromosome site, 3q26. Genomics II 1991;452-454.
6. Amitai G, Taylor P. Characterization of peripheral anionic site peptides of ChE by photoaffinity labeling with monoazidopropidium (MAP). In: Massoulie J, Bacu F, Barnard E, Chatonnet A, Doctor BP, Quinn, DM, eds. Cholinesterases: Structure, function, mechanism, genetics, and cell biology. Washington, DC: American Chemical Society, 1991.
7. Anglade F, Bizot J-C, Dodd RH, Baudoin C, Chapouthier G. Opposite effects of cholinergic agents and benzodiazepine receptor ligands in a passive avoidance task in rats. Neurosci Lett 1994;182:247-250.
8. Appleyard ME, Vercher J-E, Greenfield SA. Release of acetylcholinesterase from the guinea pig cerebellum in vivo. Neuroscience 1988;25:133-138.
9. Appleyard ME. Secreted acetylcholinesterase: non-classical aspects of a classical enzyme. Trends Neurosci 1992;15:485-490.
10. Appleyard ME, Jahnsen H. Actions of acetylcholinesterase in the guinea pig cerebellar cortex in vitro. Neuroscience 1992;47:291-301.
11. Aracava Y, Deshpande SS, Rickett DL, Brossi A, Schonenberger B, Albuquerque EX. The molecular basis of anticholinesterase actions on nicotinic and glutamatergic synapses. Ann NY Acad Sci 1987;505:226-255.
12. Argyll-Robertson D. On the calabar bean as a new agent in ophthalmic medicine. Edinburgh Med J 1863;8:815-820.
13. Arneric SP, Holladay MW, Sullivan JP. Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease. Exp Opin Invest Drugs 1996;5:79-100.
14. Ashall F, Goate AM. Role of the β-amyloid precursor protein in Alzheimer's disease. Trends Biochem Sci 1994;19:42-46.
15. Atack JR, Perry EK, Bonham JR, et al. Molecular forms of acetylcholinesterase in senile dementia of Alzheimer type: Selective loss of the intermediate (10S) form. Neurosci Lett 1983;40:199-204.
16. Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 1986;47:263-277.
17. Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH. Molecular forms of butyrylcholinesterase in the human neocortex during development and degeneration of the cortical cholinergic system. J Neurochem 1987;48:1687-1682.
18. Atack JR, Yu Q-S, Soncrant TT, Brossi A, Rapoport SI. Comparative inhibitory effects of various physostigmine analogs against acetyl-and butyrylcholinesterases. J Pharmacol Exp Therap 1989;249:194-202.
19. Atack JR, Litvan I, Thai LJ, May C, Rapoport SI, Chase TN. Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy reduced activity relative to normal subjects and lack of inhibition by oral physostigmine. J Neural Neurosurg Psychiatry 1991;54:832-835.
20. Bareggi SR, Giacobini E. Acetylcholinesterase activity in ventricular and cisternal CSF of dogs. Effect of chlorpromazine. J Neurosci Res 1978;3:335-339.
21. Bartolini A, Ocello R. Release of acetylcholine from atria isolated from guinea pigs in the presence of mipafox and eserine. Boll Soc Ital Biol Sper 1965;41:1480-1483.
22. Bartolini A, Bartolini R, Domino EF. Effects of physostigmine on brain acetylcholine content and release. Neuropharmacology 1973;12:15-25.
23. Bartus RT. Physostigmine and recent memory: effects in young and aged nonhuman primates. Science 1979;206:1087-1089.
24. Bartus RT, Dean RL, III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1997;217:408-417.
25. Bartus RT, Dean RL. Tetrahydroaminoacridine, 3,4-diaminopyridine and physostigmine: Direct comparison of effects on memory in aged primates. Neurobiol Aging 1988;9:351-356.
26. Becker RE, Giacobini E. Pharmacokinetics and pharmacodynamics of acetylcholinesterase inhibition: Can acetylcholine levels in the brain be improved in Alzheimer's disease? Drug Dev Res 1988;14:235-246.
27. Beilin B, Vatashsky E, Weinstock M. Physostigmine as an antidote for poisoning by combination of thioridazine and trihexyphenidyl. Br J Clin Pract 1985;39:400-401.
28. Berman HA, Yguerabide T, Taylor P. Fluorescence energy transfer on acetylcholinesterase: Spatial relationship between peripheral site and active center. Biochemistry 1980;19:2226-2235.
29. Berrettini WH, Garrick NA, Nurnberger JI, Jr, et al. Intravenous physostigmine increases cerebrospinal fluid neuropeptide-Y. Biol Psychiatry 1989;26:623-630.
30. Berridge MJ. Inositol lipids and calcium signaling. Proc Roy Soc Lond B 1998;234:359-378.
31. Berridge MJ. Inositol trisphosphate and calcium signaling. Nature 1993;361:315-325.
32. Bertrand N, Beley A. Effect of oxotremorine, physostigmine and scopolamine on brain acetylcholine synthesis: A study using HPLC. Neurochem Res 1990;15:1097-1100.
33. Bhat R, Turner SL, Marks MJ, Collins AC. Selective changes in sensitivity to cholinergic agonists and receptor changes elicited by continuous physostigmine infusion. J Pharmacol Exp Therap 1990;255:187-196.
34. Bliss TVP, Collingridge GL. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 1993;361:31-39.
35. Boyer AW, Somani SM. Pharmacokinetics of biliary excretion of physostigmine in rat. Arch Int Pharmacodyn 1985;278:180-192.
36. Braida D, Paladini E, Griffini P, Lamperti M, Maggi A, Sala M. An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: Comparison with other cholinesterase inhibitors. Eur J Pharmacol 1996;302:13-20.
37. Brezenoff HE, Rusin J. Brain acetylcholine mediates the hypertensive response to physostigmine in the rat. Eur J Pharmacol 1974;29:262-266.
38. Brezenoff HE, Giuliano R. Cardiovascular control by cholinergic mechanisms in the central nervous system. Ann Rev Pharmacol Toxicol 1982;22:341-381.
39. Brezenoff HE. Cardiovascular regulation by brain acetylcholine. Fed Proc 1984;43:17-20.
40. 2 muscarinic receptors lowers blood pressure in spontaneously hypertensive rats. Pharmacology 1988;36:101-105.
41. Brezenoff HE, Xiao Y-F. Acetylcholine in the posterior hypothalamic nucleus is involved in the elevated blood pressure in the spontaneously hypertensive rat. Life Sci 1989;45:1163-1170.
42. Brodie RR, Chasseaud LF, Robbins AD. Determination of physostigmine in plasma by high-performance liquid chromatography. J Chromatogr 1987;415:423-431.
43. Brossi A, Schonenberger B, Clark OE, Ray R. Inhibition of acetylcholinesterase from electric eel by (-) and (+)physostigmine and related compounds. FEBS Lett 1986;201:190-192.
44. Brown TH, Chapman PF, Kairiss EW, Keenan CL. Long-term synaptic potentiation. Science 1988;242:724-728.
45. Brownlee G, Harry J. Some pharmacological properties of the circular and longitudinal muscle strips from the guinea-pig isolated ileum. Br J Pharmacol 1963;21:544-554.
46. Buccafusco JL, Jackson WJ, Terry AV, Jr. Effects of concomitant cholinergic and adrenergic stimulation on learning and memory performance by primates. Life Sci 1992;51:7-12.
47. Buck ML, Reed MD. Use of nondepolarizing neuromuscular blocking agents in mechanically ventilated patients. Clin Pharmacol 1991;10:32-48.
48. Burks JS, Walker JE, Rumack BH, Ott JE. Tricyclic antidepressant poisoning. JAMA 1974;230:1405-1407.
49. Buxbaum JD, Oishi M, Chen HI, et al. Cholinergic agonists and interleukin-1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci USA 1992;89:10075-10078.
50. Caputi AP, Rossi F, Carney K, Brezenoff H. Modulatory effect of brain acetylcholine on reflex-induced bradycardia and tachycardia in conscious rats. J Pharmacol Exp Therap 1980;215:309-316.
51. Carlyle RF. The mode of action of neostigmine and physostigmine on the guinea pig trachealis muscle. Br J Pharmacol 1963;21:137-149.
52. Changeux J-P. Responses of acetylcholinesterase from Torpedo marmorate to salts and curarizing drugs. Mol Pharmacol 1966;2:369-392.
53. Chatonnet A, Lockridge O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem J 1989;260:625-634.
54. Chinkers M, Garbers DL. Signal transduction by guanylyl cyclases. Annu Rev Biochem 1991;60:553-575.
55. Chubb IW, Goodman S, Smith AD. Is acetylcholinesterase secreted from central neurons into the cerebrospinal fluid? Neuroscience 1976;1:57-62.
56. Clarke PBS, Reuben M, El-Bizri H. Blockade of nicotinic responses by physostigmine, tacrine and other cholinesterase inhibitors in rat striatum. Br J Pharmacol 1994;111:695-702.
57. Clemens LG, Barr P, Dohanich G. Cholinergic regulation of female sexual behavior in rats demonstrated by manipulation of endogenous acetylcholine. Physiol Behav 1989;45:437-442.
58. Clement JG. Effect of a single dose of an acetylcholinesterase inhibitor on oxotremorine-and nicotine-induced hypothermia in mice. Pharmacol Biochem Behav 1991;39:929-934.
59. Cole OF, Marquis VO. A pharmacological analysis of the responses of the gastrointestinal smooth muscle of the bat to transmural and periarterial nerve stimulation. Br J Pharmacol 1985;84:587-593.
60. Console S, Ladinsky H, Peri G, Garattini S. Effect of diazepam on mouse whole brain and brain area acetylcholine and choline levels. Eur J Pharmacol 1974;27:266-268.
61. Cordell B. β-Amyloid formation as a potential therapeutic target for Alzheimer's disease. Ann Rev Pharmacol Toxicol 1994;34:69-89.
62. Costa LG, Murphy SD. Passive avoidance retention in mice tolerant to the organophosphorus insecticide disulfotan. Toxicol Appl Pharmacol 1982;65:451-458.
63. Cox B, Hecker SE, Weston AH. Effects of two cholinesterase inhibitors on acetylcholine release from the guinea pig isolated ileum preparation. J Pharm Pharmacol 1970;22:231-232.
64. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983;219:1184-1190.
65. Crowell EB, Ketchum JS. The treatment of scopolamine-induced delirium with physostigmine. Clin Pharmacol Therap 1967;8:409-414.
66. Cuadra G, Summers K, Giacobini E. Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. J Pharmacol Exp Therap 1994;270:277-284.
67. Cummings JL, Gorman DG, Shapira J. Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry 1993;33:536-541.
68. Curley WH, Standaert FG, Dretchen KL. Physostigmine inhibition of 3′,5′-cyclic AMP phosphodiesterase from cat sciatic nerve. J Pharmacol Exp Therap 1984;228:656-661.
69. Dam M, London ED. Effects of cholinomimetics on glucose utilization in rat brain optic systems. Eur J Pharmacol 1983;87:137-140.
70. Davis BM, Brown GM, Miller M, Friesen HG, Kastin AJ, Davis KL. Effects of cholinergic stimulation on pituitary hormone release. Psychoneuroendocrinology 1982;7:347-354.
71. DeSarno P, Giacobini E, Downen M. Release of acetylcholinesterase from the caudate nucleus of the rat. J Neurosci Res 1987;18:578-590.
72. DeSarno P, Giacobini E. Modulation of acetylcholine release by nicotinic receptors in the rat brain. J Neurosci Res 1989;22:194-200.
73. Deutsch JA. The cholinergic synapse and the site of memory. Science 1971;174:788-794.
74. Deutsch JA. The cholinergic synapse and the site of memory. In: Deutsch J, ed. Physiological basis of memory. New York: Academic Press, 1983;367-386.
75. Deyi XD, Linxiu W, Shuqiu P. The inhibition and protection of cholinesterase by physostigmine and pyridostigmine against soman poisoning in vivo. Fundam Appl Toxicol 1981;1:217-221.
76. Dirnhuber P, French M, Green DM, Leadbeater L, Stratton JA. The protection of primates against soman poisoning by pretreatment with pyridostigmine. J Pharm Pharmacol 1979;31:295-299.
77. Dixon WE, Brodie TG. Contributions to the physiology of the lungs. Part I. The bronchial muscles, their innervation, and the action of drugs upon them. J Physiol 1903;27:97-111.
78. Dokla CPJ, Thai LJ. Effect of cholinesterase inhibitors on Morris water task behavior following lesions of the nucleus basalis magnocellularis. Behav Neurosci 1988;102:861-871.
79. Dokla CPJ, Rydelek-Fitzgerald L. Comparison of tetrahydroaminoacridine and physostigmine on scopolamine-induced free swim behavior in the rat. Psychopharmacology 1991;103:240-243.
80. Dragstedt CA. Trial by ordeal. Quant Bull Northwestern Univ School Med 1945;19:137-141.
81. Dumery V, Derer P, Blozovski D. Enhancement of passive avoidance learning through small doses of intra-amygdaloid physostigmine in the young rat. Its relation to the development of acetylcholinesterase. Dev Psychobiol 1988;21:553-565.
82. Elble R, Giacobini E, Scarsella GF. Cholinesterases in cerebrospinal fluid. A longitudinal study in Alzheimer disease. Arch Neurol 1987;44:403-407.
83. Elliott KAC, Pope IH, Quastel JH, eds. Neurochemistry. The chemistry of brain and nerve. Springfield, IL: Thomas, 1962.
84. Erickson CK, Burnam WL. Cholinergic alteration of ethanol-induced sleep and death in mice. Agents Actions 1971;2:8-13.
85. Exton JH. Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins. Ann Rev Pharmacol Toxicol 1996;36:481-509.
86. Flood JF, Landry DW, Jarvik ME. Cholinergic receptor interactions and their effects on long-term memory processing. Brain Res 1981;215:177-185.
87. Fox PT, Raichle ME, Mintun MA, Dence C. Nonoxidative glucose consumption during focal physiologic neural activity. Science 1988;241:462-464.
88. Frederick DL, Schulze GE, Gillam MP, Paule MG. Acute effects of physostigmine on complex operant behavior in rhesus monkeys. Pharmacol Biochem Behav 1995;50:641-648.
89. Friedland RR, Meibach RC. Effects of acetylcholinesterase inhibitors on 2-deoxy-D-glucose uptake in the rat brain. Soc Neurosci Abstr 1981;7:494.
90. Friedman MJ, Jaffe JH. A central hypothermic response to pilocarpine in the mouse. J Pharmacol Exp Therap 1969;167:34-44.
91. Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 1995;57:683-706.
92. Geaney DP, Soper N, Shepstone BJ, Cowen PJ. Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease. Lancet 1990;335:1484-1487.
93. Genovese RF. Effects of azaprophen, scopolamine, and trihexyphenidyl on schedule-controlled behavior, before and after chronic physostigmine. Eur J Pharmacol 1990;176:271-279.
94. Getman DK, Eubanks J, Camp S, Evans G, Taylor P. The human gene encoding acetylcholinesterase is located on the long arm of chromosome 7. Am J Hum Genet 1992;51:170-177.
95. Giacobini E, Somani S, McIlhany M, Downen M, Hallak M. Pharmacokinetics and pharmacodynamics of physostigmine after intravenous administration in beagle dogs. Neuropharmacology 1987;26:831-836.
96. Giacobini E, Becker R, Elble R, Mattio T, McIlhany M. Acetylcholine metabolism in brain: is it reflected by CSF changes? In: Fisher A, Hanin I, Lachman C, eds. Alzheimer and Parkinson's Diseases. New York: Plenum Press, 1986;309-316.
97. Giacobini E, Becker R, Elble R, Mattio T, McIlhany M, Scarsella G. Brain acetylcholine - a view from the cerebrospinal fluid. In: Dua N, ed. Neurobiology of Aging. New York: Plenum Press, 1987;85-102.
98. Gidda JS, Buyniski JP. Swallow-evoked peristalsis in opossum esophagus: Role of cholinergic mechanisms. Am J Physiol 1986;251:G779-G785.
99. Goldberg ND, Haddox MK. Cyclic GMP metabolism and involvement in biological regulation. Annu Rev Biochem 1977;46:823-896.
100. Gongora JL, Sierra A, Mariscal S, Aceves J. Physostigmine stimulates phosphoinositide breakdown in the rat neostriatum. Eur J Pharmacol 1988;155:49-55.
101. Gottfries CG. Neurochemical aspects of aging and diseases with cognitive impairment. J Neurosci Res 1990;27:541-547.
102. Gray PJ, Dawson RM. Kinetic constants for the inhibition of eel and rabbit brain acetylcholinesterase by some organophosphates and carbamates of military significance. Toxicol Appl Pharmacol 1987;91:140-144.
103. Green AL. A theoretical kinetic analysis of the protective action exerted by eserine and other carbamate anticholinesterases against poisoning by organophosphorus compounds. Biochem Pharmacol 1983;32:1717-1722.
104. Greenfield SA, Nedergaard S, Webb C, French M. Pressure ejection of acetylcholinesterase within the guinea pig substantia nigra has non-classical actions on the pars compacta cells independent of selective receptor and ion channel blockade. Neuroscience 1989;29:21-25.
105. Greenfield SA. A noncholinergic action of acetylcholinesterase (AChE) in the brain: From neuronal secretion to the generation of movement. Cell Mol Neurobiol 1991;11:55-77.
106. Hallak M, Giacobini E. Relation of brain regional physostigmine concentration to cholinesterase activity and acetylcholine and choline levels in rat. Neurochem Res 1986;11:1037-1048.
107. Hallak M, Giacobini E. A comparison of the effects of two inhibitors on brain cholinesterase. Neuropharmacology 1987;26:521-530.
108. Harel M, Sussman JL, Krejci E, et al. Conversion of acetylcholinesterase to butyrylcholinesterase, modeling and mutagenesis. Proc Natl Acad Sci USA 1992;89:10827-10831.
109. Haroutunian V, Barnes E, Davis KL. Cholinergic modulation of memory in rats. Psychopharmacology 1985;87:266-271.
110. Harris LW, Lennox WJ, Talbot BG, Anderson DR, Swanson DR. Toxicity of anticholinesterases: Interactions of pyridostigmine and physostigmine with soman. Drug Clin Toxicol 1984;7:507-526.
111. Harris LW, Anderson DR, Lennox WJ, Solana RP. Effects of subacute administration of physostigmine on blood acetylcholinesterase activity, motor performance, and soman intoxication. Toxicol Appl Pharmacol 1989;97:267-271.
112. Harry J. The action of drugs on the circular muscle strip from the guinea pig isolated ileum. Br J Pharmacol 1963;20:399-417.
113. Hartvig P, Wiklund L, Lindstrom B. Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. Acta Anesth Scand 1986;30:177-182.
114. Harvey AL, Rowan EG. Effects of tacrine, aminopyridines and physostigmine on acetylcholinesterase, acetylcholine release and potassium currents. Adv Neurol 1990;51:227-233.
115. Hasey G, Hanin I. Plasma corticosterone is increased and correlated with brain acetylcholine in physostigmine-but not in neostigmine-treated rats. Psychoneuroendocrinology 1990;15:3 57-369.
116. Hemsworth BA, West GB. Anticholinesterase activity of some degradation products of physostigmine. J Pharm Sci 1970;59:118-120.
117. Heyl WC, Harris LW, Stitcher DL. Effects of carbamates on whole blood cholinesterase activity: Chemical protection against soman. Drug Chem Toxicol 1980;3:319-332.
118. Hobbiger F. Pharmacology of anticholinesterase drugs. In: Zaimis E, ed. The neuromuscular junction. Heidelberg, Berlin: Springer-Verlag, 1976:487-581.
119. Hoffman WE, Albrecht RF, Miletich DJ, Hagen TJ, Cook JM. Cerebrovascular and cerebral metabolic effects of physostigmine, midazolam and a benzodiazepine antagonist. Anaesth Analgesia 1986;65:639-644.
120. Holmstedt B. The ordeal bean of old calabar: The pageant of Physostigma venenosum in medicine. In: Swain T, ed. Plants in the development of modern medicine. Cambridge, MA, 1972:303-360.
121. Honma M, Ui M. Plasma cyclic GMP: Response to cholinergic agents. Eur J Pharmacol 1978;47:1-10.
122. Hornykiewicz O, Kobinger VV. Influence of eserine, tetraethylpyrophosphate (TEPP) and neostigmine on blood pressure and the pressor carotid sinus reflex in the rat. Arch Exp Path Pharmacol 1956;228:493-500.
123. Huff FJ, Reiter CT, Rand JB. The ratio of acetylcholinesterase to butyrylcholinesterase influences the specificity of assays from each enzyme in human brain. J Neural Trans 1989;75:129-134.
124. Hunter R, Wyper DJ, Patterson J, Hansen MT, Goodwin GM. Cerebral pharmacodynamics of physostigmine in Alzheimer's disease investigated using single-photon computerized tomography. Br J Psychiatry 1991;158:351-357.
125. Hutchinson M, Kosterlitz HW, Gilbert JC. Effects of physostigmine and electrical stimulation on the acetylcholine content of the guinea pig ileum. Eur J Pharmacol 1976;39:221-235.
126. Ignarro LJ, Ballot B, Wood KS. Regulation of soluble guanylate cyclase activity by porphyrins and metalloporphyrins. J Biol Chem 1984;259:6201-6207.
127. Inagawa K. Cholinergic modulation of spatial working memory of mice in radial maze performance: Retention curve analysis. Jpn J Psychopharmacol 1993;13:233-238.
128. Inestrosa NC, Alvarez A, Perez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 1996;16:881-891.
129. Ito S, Kimura A, Ohga A. Development of non-cholinergic, non-adrenergic excitatory and inhibitory responses to intramural nerve stimulation in rat stomach. Br J Pharmacol 1988;93:684-692.
130. Ito T, Miura Y, Kadokawa T. Physostigmine induces in rats a phenomenon resembling long-term potentiation. Eur J Pharmacol 1988;156:351-359.
131. Ito T, Miura Y, Kadokawa T. Effects of physostigmine and scopolamine on long-term potentiation of hippocampal population spikes in rats. Can J Physiol Pharmacol 1988;66:1010-1016.
132. Janowsky DS, Risch SC. Cholinomimetic and anticholinergic drugs used to investigate an acetylcholine hypothesis of affective disorders and stress. Drug Dev Res 1984;4:125-142.
133. Jastak JT. Physostigmine: An antidote for excessive central nervous system depression or paradoxical rage reactions resulting from intravenous diazepam. Anesthesia Prog 1985;32:87-92.
134. Joyce PR, Donald RA, Nicholls MG. Physostigmine reduces the plasma cortisol response to methylphenidate in normal subjects. J Psychiat Res 1986;20:151-157.
135. Kalow W. Pharmacogenetics: Past and future. Life Sci 1990;47:1385-1397.
136. Karczmar AG. Properties of anticholinesterase agents. In: Root WS, Hofman EF, eds. Physiological pharmacology, vol III, pt C. New York/London: Academic Press, 1967:163-322.
137. Katz B, Miledi R. Transmitter leakage from motor nerve endings. Proc. Roy Soc Lond B 1977;196:59-72.
138. Keeler JR, Hurst CG, Dunn MA. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. JAMA 1991;266:693-695.
139. Kendall DA, Nahorski SR. Depolarization-evoked release of acetylcholine can mediate phosphoinositide hydrolysis in slices of rat cerebral cortex. Neuropharmacology 1987;26:513-519.
140. Kerwin JF, Jr, Lancaster JR, Jr, Feldman PL. Nitric oxide: A new paradigm for second messengers. J Med Chem 1995;36:4343-4362.
141. Knapp S, Wardlow ML, Albert K, Waters D, Thai J. Correlation between plasma physostigmine concentrations and percentage of acetylcholinesterase inhibition over time after controlled release of physostigmine in volunteer subjects. Drug Metab Dispos 1991; 19:400-404.
142. Koelle GB, Koelle ES, Friedenwald JS. The effect of inhibition of specific and nonspecific cholinesterase on the motility of the isolated ileum. J Pharmacol Exp Therap 1950;100:180-191.
143. Koelle GB. Autonomie and pharmacologic control of colonic activity. Ann NY Acad Sci 1954;58:307-316.
144. Koster R. Synergisms and antagonisms between physostigmine and di-isopropyl fluorophosphate in cats. J Pharmacol Exp Therap 1946;88:39-46.
145. Kronfeld PC. Eserine and pilocarpine: Our 100 year old allies. Survey Ophthalmol 1970;14:479-485.
146. Kumar V, Smith RC, Sherman KA, et al. Cortisol responses to cholinergic drugs in Alzheimer's disease. Int J Clin Pharmacol Therap Toxicol 1988;26:471-476.
147. Lapetina EG, Michell RH. Stimulation by acetylcholine of phosphatidylinositol, labeling. Subcellular distribution in rat cerebral-cortex slices. Biochem J 1972;126:1141-1147.
148. Lawrence GD, Yatim N. Extraction of physostigmine from biologic fluids and analysis by liquid chromatography with electrochemical detection. J Pharmacol Methods 1990;24:137-143.
149. Lee J-H, Turndorf H, Poppers PJ. Physostigmine reversal of antihistamine-induced excitement and depression. Anesthesiology 1975;43:683-684.
150. Lim D-K, Fernando JCR, Hoskins B, Ho IK. Quantitative assessment of tolerance development to diisopropylfluorophosphate. Pharmacol Biochem Behav 1987;26:281-286.
151. Lim D-K, Ito Y, Yu ZJ, Hoskins B, Ho IK, Prevention of soman toxicity after the continuous administrations of physostigmine. Pharmacol Biochem Behav 1989;31:633-639.
152. Lindsay RM, Wiegand SJ, Altar CA, DiStefano PS. Neurotrophic factors from molecule to man. Trends Neurosci 1994;17:182-190.
153. Lindvall O, Kokaia Z, Bengzon J, Elmer E, Kokaia M. Neurotrophins and brain insults. Trends Neurosci 1994;170:490-496.
154. Lockridge O, La Du BN. Comparison of atypical and usual human serum cholinesterase: Purification, number of active sites, substrate affinity and turnover number. J Biol Chem 1978;253:361-366.
155. Lockridge O. Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol Ther 1990;47:35-60.
156. Loewenstein Y, Gnatt A, Neville LF, Soreq H. Chimeric human cholinesterase. Identification of interaction sites responsible for recognition of acetyl-or butyrylcholinesterase-specific ligands. J Mol Biol 1993;234:289-296.
157. Loewenstein Y, Gnatt A, Neville LF, Zakut H, Soreq H. Structure function relationship studies in human cholinesterase reveal genomic origins for individual variations in cholinergic drug responses. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:905-926.
158. Loewi O, Navratil E. Physostigmine and ergotamine. Brief Sci Report Klin Wschr 1926;5:894-899.
159. Lomax P, Jenden DJ. Hypothermia following systemic and intracerebral injection of oxotremorine in the rat. Int J Neuropharmacol 1966;5:353-359.
160. Lukey BJ, Parrish JH, Marlow DD, Clark CR, Sidell FR. Pharmacokinetics of physostigmine intramuscularly administered to guinea pigs. J Pharm Sci 1990;79:796-798.
161. Mandel RJ, Chen AD, Connor DJ, Thai LJ. Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis. Effects on performance in the water maze task and cortical cholinergic markers. Pharmacol Exp Therap 1989;251:612-619.
162. Marta M, Gatta F, Pomponi M. Physostigmine analogs anticholinesterases: Effects of the lengthening of the N-carbamic chain on the inhibition kinetics. Biochim Biophys Acta 1992;1120:262-266.
163. Massoulie J, Bon S. The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. Anna Rev Neurosci 1982;5:57-106.
164. Massoulie J, Toutant JP. Vertebrate cholinesterases: Structure and types of interaction. In: Whittaker VP, ed. The cholinergic synapse. Berlin: Springer-Verlag, 1988.
165. Massoulie J, Pezzementi L, Bon S, Krejci E, Vallette FM. Molecular and cellular biology of cholinesterases. Prog Neurobiol 1993;41:31-91.
166. Matsuoka N, Maeda N, Ohkubo Y, Yamaguchi I. Differential effects of physostigmine and pilocarpine on the spatial memory deficits produced by two septo-hippocampal deafferentations in rats. Brain Res 1991;559:233-240.
167. Matthew CB, Hubbard RW, Francesconi RP, Thomas GJ. Carbamate-induced performance and thermoregulatory decrements restored with diazepam and atropine. Aviat Space Environ Med 1987;58:1183-1187.
168. Matthew CB, Francesconi RP, Hubbard RW. Physostigmine: Dose-response effects on endurance and thermoregulation during exercise. Life Sci 1991;50:39-44.
169. Maxwell DM, Brecht KM, Lenz DE. Effect of carboxylesterase inhibition on carbamate protection against soman toxicity. J Pharmacol Exp Therap 1988;240:986-991.
170. McGuire MC, Nogveira CP, Bartels CF, et al. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci USA 1989;86:953-957.
171. Megazzini P, Bernardi G, Ballotti PL. Regional changes of the cholinergic system in the guinea pig's brain after physostigmine. Experientia 1965;21:406-408.
172. Melmon KL, Morrelli HF, eds. Clinical pharmacology, 2nd ed. New York: Macmillan, 1978:435.
173. Menezes AMS, Rao VS. Effect of Astromum urundeuva (Aroeira) on gastrointestinal transit in mice. Brazil J Med Biol Res 1988;21:531-533.
174. Mesulam MM, Geula C, Asuncion-Moran M. Anatomy of cholinesterase inhibition in Alzheimer's disease: Effect of physostigmine and tetrahydroaminoacridine on plaques and tangles. Ann Neurol 1987;22:683-691.
175. Mesulam MM, Moran MA. Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease. Ann Neurol 1987;22:223-∧228.
176. Meyer HG, Lukey BJ, Gepp RT, McCluskey MP, Lieske CN. Development and application of a radioimmunoassay for physostigmine. J Pharmacol Exp Therap 1989;251:606-611.
177. Miller RL, Verma PS. A radioimmunoassay for physostigmine in biological fluids and tissues. J Pharm Biomed Anal 1989;7:955-963.
178. Miller SA, Blick DW, Kerenyi SZ, Murphy MR. Efficacy of physostigmine as a pretreatment for organophosphate poisoning. Pharmacol Biochem Behav 1993;44:343-347.
179. Miyamoto M, Narumi S, Nagaoka A, Coyle JT. Effects of continuous infusion of cholinergic drugs on memory impairment in rats with basal forebrain lesions. J Pharmacol Exp Therap 1989;248:825-835.
180. Mori F, Lai C-C, Fusi F, Giacobini E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. NeuroReport 1995;6:633-636.
181. Mount HTJ, Dreyfus CF, Black IB. Muscarinic stimulation promotes cultured Purkinje cell survival: A role for acetylcholine in cerebellar development? J Neurochem 1994;63:2065-2073.
182. Munoz RA. Treatment of tricyclic intoxication. Am J Psychiatry 1976;133:1085-1088.
183. Murray T, Cross AJ, Green AR. Reversal by tetrahydroaminoacridine of scopolamine-induced memory and performance deficits in rats. Psychopharmacology 1991;105:134-136.
184. Murray A, Cottrell DF, Woodman MP. Cholinergic activity of intestinal muscle in vitro taken from horses with and without equine grass sickness. Vet Res Comm 1994; 18:199-207.
185. Nabeshima T, Tohyama K, Ichihara K, Kameyama T. Effects of benzodiazepines on passive avoidance response and latent learning in mice: Relationship to benzodiazepine receptors and the cholinergic neuronal system. J Pharmacol Exp Therap 1990;255:789-794.
186. Nelson SR, Doull J, Tockman BA, Cristiano PJ, Samson FE. Regional brain metabolism changes induced by acetylcholinesterase inhibitors. Brain Res 1978;157:186-190.
187. Neville LF, Gnatt A, Loewenstein Y, Seidman S, Ehrlich G, Soreq H. Intramolecular relationship in cholinesterases revealed by oocyte expression of site-directed and natural variants of human BChE. EMBO J 1992;11:1641-1649.
188. Newton RW. Physostigmine salicylate in the treatment of tricyclic-antidepressant overdosage. JAMA 1975;231:941-943.
189. Nicholson CD. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 1990;101:147-159.
190. Nickalls RWD, Nickalls EA. The first use of physostigmine in the treatment of atropine poisoning. Anaesthesia 1988;43:776-779.
191. Nilsen OG. Serum albumin and lipoproteins as the quinidine binding molecules in normal human sera. Biochem Pharmacol 1976;25:1007-1012.
192. 3H]acetylcholine efflux from Alzheimer brain slices to normal level. J Neurol Transm 1986;67:275-285.
193. Nilsson L, Adem A, Hardy J, Winblad B, Nordberg A. Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors? J Neurol Trans 1987;70:357-368.
194. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258:607-614.
195. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992;258:304-307.
196. Ogane N, Giacobini E, Messamore E. Preferential inhibition of acetylcholinesterase molecular forms in rat brain. Neurochem Res 1992;17:489-495.
197. Ohta H, Ni X-H, Matsumoto K, Watanabe H. Working memory deficit in aged rats in delayed non-matching to position task and effect of physostigmine on performance of young and aged rats. Jpn J Pharmacol 1991;56:303-309.
198. Ono M, Minamoto Y, Shibata S, Watanabe S. Attenuating effect of arecoline
199. Osman MY, Abdel Tawab SM, Sharaf IA. Effect of physostigmine on cholinesterase activity in different parts of rat brain. Arz Forsch 1995;45:663-665.
200. Overstreet DH, Schiller G. Behavioral compensation, muscarinic receptors and tolerance development to physostigmine. Soc Neurosci Abstr 1979;5:658.
201. Pacheco G, Palacios-Esquivel R, Moss DE. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: Selectivity towards human brain acetylcholinesterase compared with butyrylcholinesterase. J Pharmacol Exp Therap 1995;274:767-770.
202. Pereira EFR, Alkondon M, Tano T, et al. A novel agonist binding site on nicotinic acetylcholine receptors. J Recep Res 1993;13:413-436.
203. Pereira EFR, Reinhardt-Maelicke S, Schrattenholz A, Maelicke A, Albuquerque EX. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J Pharmacol Exp Therap 1993;265:1474-1491
204. Perry EK, Smith CJ, Court JA, Bonham JR, Rodway M, Atack JR. Interaction of 9-amino-1,2,3,4-tetrahydroaminoacridine (THA) with human cortical nicotinic and muscarinic receptor binding in vitro. Neurosci Lett 1988;91:211-216.
205. Pinchasi I, Maayani S, Sokolovsky M. On the interaction of drugs with the cholinergic nervous system. III. Tolerance to phencyclidine derivatives: In vivo and in vitro studies. Biochem Pharmacol 1977;26:1671-1679.
206. Ramaswamy S, Shewade DG, Tripathi CD, Tyagi MG, Tripathi KD. A study on the vasopressin induced delay in the gastrointestinal transit in mice: Possible mechanism of action. Life Sci 1993;53:991-996.
207. Reents S, Seymour J. Physostigmine. In: Clinical pharmacology. Gainesville, FL: Gold Standard Multimedia Inc, 1996.
208. Risch SC, Cohen RM, Janowsky DS, Kalin NH, Murphy DL. Mood and behavioral effects of physostigmine on humans are accompanied by elevations in plasma β-endorphin and cortisol. Science 1980;209:1545-1546.
209. Ritzmann RF, Glasky A, Steinberg A, Melchior CL. The interactions of ethanol with the cognitive enhancers tacrine, physostigmine and AIT-082. J Gerontol 1994;49:B51-B53.
210. Rooney TA, Nahorski SR. Regional characterization of agonist and depolarization-induced phosphoinositide hydrolysis in rat brain. J Pharmacol Exp Therap 1986;239:873-880.
211. Rosenberry TL. Acetylcholinesterase. Adv Enzymol 1975;43:103-213.
212. Rumack BH. Anticholinergic poisoning: Treatment with physostigmine. Pediatrics 1973;52:449-451.
213. Rupniak NMJ, Steventon MJ, Field MJ, Jennings CA, Iversen SD. Comparison of the effects of four cholinomimetic agents on cognition in primates following disruption by scopolamine or by lists of objects. Psychopharmacology 1989;99:189-195.
214. Rupniak NMJ, Field MJ, Samson NA, Steventon MJ, Iversen SD. Direct comparison of cognitive facilitation by physostigmine and tetrahydroaminoacridine in two primate models. Neurobiol Aging 1990;11:609-613.
215. Rupreht J. Physostigmine reversal of diazepam. Anesthesiology 1980;53:180-181.
216. Rush DK, Streit K. Memory modulation with peripherally acting cholinergic drugs. Psychopharmacology 1992;106:375-382.
217. Russell RW, Vasquez BJ, Overstreet DH, Dalglish FW. Consummatory behavior during tolerance to and withdrawal from chronic depression of cholinesterase activity. Physiol Behav 1971;7:523-528.
218. Russell RW, Overstreet DH, Cotman CW, et al. Experimental tests of hypotheses about neurochemical mechanisms underlying behavioral tolerance to the anticholinesterase, diisopropylfluorophosphate. J Pharmacol Exp Therap 1975;192:73-85.
219. Sachar EJ, Puig-Antich J, Ryan ND. et al. Three tests, of cortisol secretion in adult endogenous depressives. Acta Psychiat Scand 1985;71:1-8.
220. Salerno PR, Coon JM. A pharmacologic comparison of hexaethyltetraphosphate (HETP), tetraethylpyrophosphate (TEPP) with physostigmine, neostigmine, and DFP. J Pharmacol Exp Therap 1949;95:240-255.
221. Sano M, Bell K, Marder K, Stricks L, Stem Y, Mayeux R. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease. Clin Neuropharmacol 1993; 16:61-69.
222. Sansone M, Castellano C, Palazzesi S, Battaglia M, Ammassari-Teule M. Effects of oxiracetam, physostigmine, and their combination on active and passive avoidance learning in mice. Pharmacol Biochem Behav 1993;44:451-455.
223. Sansone M, Battaglia M, Vetulani J. Shuttle-box avoidance behavior of mice treated with nifedipine in combination with nicotine or physostigmine. Pol J Pharmacol 1994;46:169-173.
224. Santucci AC, Kanof PD, Haroutunian V. Effect of physostigmine on memory consolidation and retrieval processes in intact and nucleus basalis-lesioned rats. Psychopharmacology 1989;99:70-74.
225. Sarter M, Bodewitz G, Stephens DN. Attenuation of scopolamine-induced impairment of spontaneous alternation behaviour by antagonist but not inverse agonist and agonist β-carbolines. Psychopharmacology 1988;94:491-495.
226. Sarter M. Taking stock of cognition enhancers. Trends Pharmacol Sci 1991;12:456-461.
227. Schatz CR, Geula C, Mesulam M. Competitive substrate inhibition in the histochemistry of cholinesterase activity in Alzheimer's disease. Neurosci Lett 1990;117:56-61.
228. Schrattenholz A, Coban T, Schroder B, et al. Biochemical characterization of a novel channel-activating site on nicotinic acetylcholine receptors. J Recep Res 1993;13:393-412.
229. Schrattenholz A, Godovac-Zimmermann J, Schafer HJ, Albuquerque EX, Maelicke A. Photoaffinity labeling of Torpedo acetylcholine receptor by physostigmine. Eur J Biochem 1993;216:671-677.
230. Segre S, Cerretani D, Baldi A, Urso R. Pharmacokinetics of heptastigmine in rats. Pharmacol Res 1992;25:139-146.
231. Selkoe DJ. Alzheimer's disease: A central role for amyloid. J Neuropathol Exp Neurol 1994;53:438-447.
232. Shapiro RA, Tietje KM, Subers EM, Scherer NM, Habecker BA, Nathanson NM. Regulation of muscarinic acetylcholine receptor function in cardiac cells and in cells expressing cloned receptor genes. Trends Pharmacol Sci 1989(Suppl);43-46.
233. Shaw KP, Aracava Y, Akaike A, Daly JW, Rickett DL, Albuquerque EX. The reversible cholinesterase inhibitor physostigmine has channel blocking and agonist effects on the acetylcholine receptor-ion channel complex. Mol Pharmacol 1985;28:527-538.
234. Sherby SM, Eldefrawi AT, Albuquerque EX, Eldefrawi ME. Comparison of the actions of carbamate anticholinesterases on the nicotinic acetylcholine receptor. Mol Pharmacol 1984;27:343-348.
235. Shibata S, Minamoto Y, Ono M, Watanabe S. Age-related impairment of food anticipatory locomotor activity in rats. Physiol Behav 1994;55:875-878.
236. Slovis TL, Ott JE, Teitelbaum DT, Lipscomb W. Physostigmine therapy in acute tricyclic antidepressant poisoning. Clin Toxicol 1971;4:451-459.
237. Small DH. Non-cholinergic actions of acetylcholinesterases: Proteases regulating cell growth and development? Trends Biochem Sci 1990;15:213-216.
238. Smiler BG, Bartholomew EG, Sivak BJ, Alexander GD, Brown EM. Physostigmine reversal of scopolamine delirium in obstetric patients. Am J Obset Gynecol 1973; 16:326-329.
239. Somani SM, Boyer A. Urinary pharmacokinetics of physostigmine in the rat. Eur J Drug Metab Pharmacokinet 1985;10:343-349.
240. Somani SM, Unni LK, Khalique A. Time course of physostigmine metabolism in plasma and tissues after i.v. administration. Pharmacologist 1985;27:396.
241. Somani SM, Khalique A. Distribution and pharmacokinetics of physostigmine in rat after intramuscular administration. Fund Appl Toxicol 1986;6:327-334.
242. Somani SM, Khalique A. Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration. Drug Metab Dispos 1987;15:627-633.
243. Somani SM, Unni LK, McFadden DL. Drug interaction for plasma protein binding: Physostigmine and other drugs. Int J Clin Pharmacol Therap Toxicol 1987;25:412-416.
244. Somani SM. Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. Biopharm Drug Dispos 1989;10:187-203.
245. Somani SM, Dube SN. In vivo dose-response relationship between physostigmine and cholinesterase activity in RBC and tissues of rats. Life Sci 1989;44:1907-1915.
246. Somani SM, Dube SN. Physostigmine - An overview as pretreatment drug for organophosphate intoxication. Int J Clin Pharmacol Therap Toxicol 1989;27:367-387.
247. Somani SM, Gupta SK, Khalique A, Unni LK. Physiological pharmacokinetic and pharmacodynamic model of physostigmine in the rat. Drug Metab Dispos 1991;19:655-660.
248. Soreq H, Zakut H. Cholinesterase Genes: Multileveled regulation. Monogr Human Genet 1990;13:1-120.
249. Stamenovic BA, Varagic VM. The effect of eserine on the efferent neuronal activity in the cervical sympathetic of the rat. Neuropharmacology 1970;9:561-566.
250. Stanes MD, Brown CP, Singer G. Effect of physostigmine on Y-maze discrimination retention in the rat. Psychopharmacology 1976;46:269-276.
251. Stedman E, Barger G. Physostigmine (eserine). Part III. J Chem Soc 1925;127:247-258.
252. Stedman E, Stedman E, Easson LH. Cholinesterase. An enzyme present in the blood serum of the horse. Biochem J 1932;26:2056-2066.
253. Stolerman IP, Mirza NR, Shoaib M. Nicotine psychopharmacology: Addiction, cognition and neuroadaptation. Med Res Revs 1995;15:47-72.
254. Taira CA, Enero MA. Interaction between clonidine and physostigmine in normal rats and in rats after sinoaortic denervation. Naunyn-Schmied Arch Pharmacol 1989;339:522-527.
255. Tavitian B, Pappata S, Planas AM, et al. In vivo visualization of acetylcholinesterase with positron emission tomography. NeuroReport 1993;4:535-538.
256. Taylor P. The cholinesterases. J Biol Chem 1991;266:4025-4028.
257. Taylor P, Radic Z. The cholinesterases: from genes to proteins. Annu Rev Pharmacol Toxicol 1994;34:281-320.
258. Taylor P. Anticholinesterase agents. In: Gilman JG, Hardman LE, Limbind PB, Molinott RW, Ruddon, eds, The pharmacological basis of therapeutics. New York: Macmillan, 1996:161-176.
259. Terry AV Jr, Jackson WJ, Buccafusco JJ. Effects of concomitant cholinergic and adrenergic stimulation on learning and memory performance by young and aged monkeys. Cereb Cortex 1993;3:304-312.
260. Thomsen T, Kaden B, Fischer JP, et al. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine, and tacrine. Eur J Clin Chem Clin Biochem 1991;29:487-492.
261. Trendelenburg P. Physiological and pharmacological studies on isolated bronchial muscle. Arch Exp Path Pharmacol 1912;69:79-108.
262. Tune L, Brandt J, Frost J, et al. Physostigmine in Alzheimer's disease: Effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and central-bipod flow analyzed by single photon emission tomography. Acta Psychiat Scand 1991;366(Suppl):61-65.
263. Ulvestad A, Gerner T. Inhibitory effects of dopamine and isoprenaline on antral motor activity stimulated by acetylcholine or physostigmine in vitro. Scand J Gastroenterol 1985;20:243-246.
264. Unni LK, Somani SM. Binding of physostigmine to rat and human plasma and crystalline serum albumins. Life Sci 1985;36:1389-1396.
265. Unni LK, Somani SM. Hepatic and muscle clearance of physostigmine in the rat. Drug Metab Dispos 1986;14:183-189.
266. Urba-Holmgren R, Gonzalez RM, Holmgren B. Is yawning a cholinergic response? Nature 1977;267:261-262.
267. Urba-Holmgren R, Santos A, Holmgren B, Eguibar JR, Two inbred rat sublines that differ in spontaneous yawning behavior also differ in their responses to cholinergic and dopaminergic drugs. Behav Brain Res 1993;56:155-159.
268. Ushijima I, Yamada K, Inoue T, Tokunaga T, Furukawa T, Noda Y. Muscarinic and nicotinic effects on yawning and tongue protruding in the rat. Pharmacol Biochem Behav 1984;21:297-300.
269. Ushijima I, Mizuki Y, Yamada M. Multifocal sites of action involved in dopaminergic-cholinergic neuronal interactions in yawning. Psychopharmacology 1988;95:34-37.
270. Varagic VM, Terzic M, Mrsulja BB. The effect of physostigmine and neostigmine on the concentration of glycogen in the liver of the rat. Naunyn-Schmied Arch Pharmacol 1967;258:229-237.
271. Varagic VM, Stojanovic V. The effect of enkephalins and of beta-endorphin on the hypertensive response to physostigmine in the rat. Br J Pharmacol 1987;92:197-202.
272. Vargas HM, Brezenoff HE. Suppression of hypertension during chronic reduction of brain acetylcholine in spontaneously hypertensive rats. J Hypertension 1988;6:739-745.
273. Volger BW. Alternatives in the treatment of memory loss in patients with Alzheimer's disease. Clin Pharmac 1991;10:447-456.
274. Waite JJ, Thai LJ. The behavioral effects of heptylphysostigmine on rats lesioned in the nucleus basalis. Neurosci Res 1995;21:251-259.
275. Wallace W, Ahlers ST, Gotlib J, et al. Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. Proc Natl Acad Sci USA 1993;90:8712-8716.
276. Walker MB. Treatment of myasthenia gravis with physostigmine. Lancet 1934;1:1200-1201.
277. Walker WE, Levy RC, Hanenson IB. Physostigmine - Its use and abuse. JACEP 1976;5:436-439.
278. Wanibuchi F, Nishida T, Yamashita H, et al. Characterization of a novel muscarinic receptor agonist, YM 796: Comparison with cholinesterase inhibitors in in vivo pharmacological studies. Eur J Pharmacol 1994;265:151-158.
279. Weisdorf D, Kramer J, Goldbarg A, Klawans H. Physostigmine for cardiac and neurologic manifestations of phenothiazine poisoning. Clin Pharmacol Ther 1978;24:663-667.
280. Whelpton R, Moore T. Sensitive liquid chromatographic method for physostigmine in biological fluids using dual-electrode electrochemical detection. J Chromatogr 1985;341:361-371.
281. Whelpton R, Hurst P. Bioavailability of oral physostigmine. N Engl J Med 1985;313:1293-1294.
282. Whelpton R, Hurst PR. The binding of physostigmine to human serum albumin. J Pharm Pharmacol 1990;42:804-805.
283. Whittaker M. Cholinesterase. Basel: Karger, 1986.
284. Whittaker VP. The cholinergic synapse. Berlin, New York: Springer-Verlag, 1988.
285. Worley PF, Baraban JM, McCarren M, Snyder SH, Alger BE. Cholinergic phosphatidylinositol modulation of inhibitory, G-protein-linked, neurotransmitter actions: Electrophysiological studies in rat hippocampus. Proc Natl Acad Sci USA 1987;84:3467-3471.
286. Worms P, Gueudet C, Perio A, Soubrie P. Systemic injection of pirenzepine induces a deficit in passive avoidance learning in rats. Psychopharmacology 1989;98:286-288.
287. Yamada S, Isogai M, Okudaira H, Hayashi E. Correlation between cholinesterase inhibition and reduction in muscarinic receptors and choline uptake by repeated diisopropylfluorophosphate administration: Antagonism by physostigmine and atropine. J Pharmacol Exp Therap 1983:226:519-525.
288. Yoshida S, Suzuki N. Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats. Eur J Pharmacol 1993;250:117-124.
289. Zarrindast M, Poursoltan M. Interactions of drugs acting on central dopamine receptors and cholinoceptors on yawning responses in the rat induced by apomorphine, bromocriptine or physostigmine. Br J Pharmacol 1989;96:843-848.
290. 2 receptor-activation in rats. Br J Pharmacol 1992;105:675-678.
291. Physicians Desk Reference. Des Moines, Iowa: Medical Economics Press, 1996:1009.